A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Summary

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A*02 expression.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Solid Tumor, Adult
• Colorectal Cancer
• NSCLC
• Non Small Cell Lung Cancer
• NSCLC, Recurrent
• Non-Small Cell Squamous Lung Cancer
• Pancreas Cancer
• Pancreatic Neoplasm
• Colorectal Adenocarcinoma
• CRC
• Colon Cancer
• Rectal Cancer
• Cancer
• Ovarian Cancer
• Ovarian Neoplasms
• Mesothelioma
• Mesothelioma, Malignant
• Ovary Cancer
• Lung Cancer
• MESOM

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

A2 Biotherapeutics Inc.

Last updated on ClinicalTrials.gov

June 12, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites